SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
In this medfyle
Metabolic and haemodynamic changes with SGLT2 inhibition.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Diabetes®, an official journal of the American Diabetes Association®, and is published in coordination with Sheridan. This MedFyle was created by GlobalPort (International) Limited with permission from the American Diabetes Association; neither Sheridan nor the American Diabetes Association takes any responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by John Wilding, DM, FRCP, University of Liverpool, Liverpool, UK.
Original article:
SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial. Katrine M. Lauritsen, Bent R.R. Nielsen, Lars P. Tolbod, Mogens Johannsen, Jakob Hansen, Troels K. Hansen, Henrik Wiggers, Niels Møller, Lars C. Gormsen, Esben Søndergaard. Diabetes Mar 2021, 70 (3) 800-808; DOI: 10.2337/db20-0921
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Diabetes Association.
This activity is supported by an educational grant from Lilly.
